Logo image of AIM

AIM IMMUNOTECH INC (AIM) Stock Fundamental Analysis

USA - NYSEARCA:AIM - US00901B3033 - Common Stock

2.65 USD
-0.03 (-1.12%)
Last: 10/2/2025, 8:04:00 PM
Fundamental Rating

1

Overall AIM gets a fundamental rating of 1 out of 10. We evaluated AIM against 536 industry peers in the Biotechnology industry. AIM may be in some trouble as it scores bad on both profitability and health. AIM is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

AIM had negative earnings in the past year.
AIM had a negative operating cash flow in the past year.
AIM had negative earnings in each of the past 5 years.
AIM had a negative operating cash flow in each of the past 5 years.
AIM Yearly Net Income VS EBIT VS OCF VS FCFAIM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M

1.2 Ratios

AIM has a Return On Assets of -243.41%. This is amonst the worse of the industry: AIM underperforms 92.16% of its industry peers.
Industry RankSector Rank
ROA -243.41%
ROE N/A
ROIC N/A
ROA(3y)-132.89%
ROA(5y)-90.82%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
AIM Yearly ROA, ROE, ROICAIM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 1K 1.5K

1.3 Margins

AIM's Gross Margin of 77.40% is amongst the best of the industry. AIM outperforms 83.77% of its industry peers.
The Profit Margin and Operating Margin are not available for AIM so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 77.4%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
AIM Yearly Profit, Operating, Gross MarginsAIM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -5K -10K -15K

More info and screens

0

2. Health

2.1 Basic Checks

AIM does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, AIM has more shares outstanding
AIM has less shares outstanding than it did 5 years ago.
The debt/assets ratio for AIM is higher compared to a year ago.
AIM Yearly Shares OutstandingAIM Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
AIM Yearly Total Debt VS Total AssetsAIM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

AIM has an Altman-Z score of -106.72. This is a bad value and indicates that AIM is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -106.72, AIM is not doing good in the industry: 96.08% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -106.72
ROIC/WACCN/A
WACC9.8%
AIM Yearly LT Debt VS Equity VS FCFAIM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M

2.3 Liquidity

A Current Ratio of 0.26 indicates that AIM may have some problems paying its short term obligations.
Looking at the Current ratio, with a value of 0.26, AIM is doing worse than 94.40% of the companies in the same industry.
A Quick Ratio of 0.26 indicates that AIM may have some problems paying its short term obligations.
The Quick ratio of AIM (0.26) is worse than 94.22% of its industry peers.
Industry RankSector Rank
Current Ratio 0.26
Quick Ratio 0.26
AIM Yearly Current Assets VS Current LiabilitesAIM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

More info and screens

4

3. Growth

3.1 Past

AIM shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -452.42%.
The Revenue for AIM has decreased by -15.84% in the past year. This is quite bad
AIM shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 3.96% yearly.
EPS 1Y (TTM)-452.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%8%
Revenue 1Y (TTM)-15.84%
Revenue growth 3Y7.99%
Revenue growth 5Y3.96%
Sales Q2Q%-50%

3.2 Future

AIM is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 15.20% yearly.
Based on estimates for the next years, AIM will show a very strong growth in Revenue. The Revenue will grow by 281.45% on average per year.
EPS Next Y6.9%
EPS Next 2Y8.7%
EPS Next 3Y24.31%
EPS Next 5Y15.2%
Revenue Next Year37.93%
Revenue Next 2Y17.44%
Revenue Next 3Y306.65%
Revenue Next 5Y281.45%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
AIM Yearly Revenue VS EstimatesAIM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 100M 200M 300M
AIM Yearly EPS VS EstimatesAIM Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -10 -20 -30 -40

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for AIM. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for AIM. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AIM Price Earnings VS Forward Price EarningsAIM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AIM Per share dataAIM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5 -10 -15 -20 -25

4.3 Compensation for Growth

AIM's earnings are expected to grow with 24.31% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y8.7%
EPS Next 3Y24.31%

More info and screens

0

5. Dividend

5.1 Amount

AIM does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AIM IMMUNOTECH INC

NYSEARCA:AIM (10/2/2025, 8:04:00 PM)

2.65

-0.03 (-1.12%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-14 2025-08-14/amc
Earnings (Next)11-13 2025-11-13
Inst Owners0.45%
Inst Owner Change-99.25%
Ins Owners3.27%
Ins Owner Change1.13%
Market Cap7.18M
Analysts80
Price Target153 (5673.58%)
Short Float %0.31%
Short Ratio0.03
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)26.01%
Min EPS beat(2)13.9%
Max EPS beat(2)38.12%
EPS beat(4)4
Avg EPS beat(4)39.14%
Min EPS beat(4)13.9%
Max EPS beat(4)67.89%
EPS beat(8)5
Avg EPS beat(8)5.95%
EPS beat(12)7
Avg EPS beat(12)1.49%
EPS beat(16)7
Avg EPS beat(16)-5.2%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-9900%
EPS NY rev (1m)38.98%
EPS NY rev (3m)-5304.29%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 49.19
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-25.08
EYN/A
EPS(NY)-16.8
Fwd EYN/A
FCF(TTM)-4.62
FCFYN/A
OCF(TTM)-4.59
OCFYN/A
SpS0.05
BVpS-1.42
TBVpS-2.26
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -243.41%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 77.4%
FCFM N/A
ROA(3y)-132.89%
ROA(5y)-90.82%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.26
Quick Ratio 0.26
Altman-Z -106.72
F-Score4
WACC9.8%
ROIC/WACCN/A
Cap/Depr(3y)119.66%
Cap/Depr(5y)104.37%
Cap/Sales(3y)164.13%
Cap/Sales(5y)265.26%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-452.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%8%
EPS Next Y6.9%
EPS Next 2Y8.7%
EPS Next 3Y24.31%
EPS Next 5Y15.2%
Revenue 1Y (TTM)-15.84%
Revenue growth 3Y7.99%
Revenue growth 5Y3.96%
Sales Q2Q%-50%
Revenue Next Year37.93%
Revenue Next 2Y17.44%
Revenue Next 3Y306.65%
Revenue Next 5Y281.45%
EBIT growth 1Y47.07%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y27.57%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y26.99%
OCF growth 3YN/A
OCF growth 5YN/A